0.05Open0.05Pre Close1 Volume0 Open Interest7.00Strike Price5.00Turnover319.67%IV20.21%PremiumAug 9, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0748Delta0.1009Gamma174.20Leverage Ratio-0.1046Theta0.0000Rho-13.02Eff Leverage0.0006Vega
Inovio Pharmaceuticals Stock Discussion
Inovio Receives Advanced Therapy Medicinal Product Certificate From European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate Ino-3107
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet